secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2024-09-06T23:59:59+00:00
Accession:  0001493152-24-035285
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem and Aditxt amend merger agreement again; extend equity investment and closing deadlines
--------------------------------------------------------------------------------

- Third Parent Equity Investment date moved from Sept 6 to Sept 30, 2024; Fourth from Sept 30 to Oct 31, 2024.
- Outside consummation date (Section 8.1(b)(ii)) extended to November 29, 2024.
- Aditxt must purchase $1.5M of Series F-1 preferred stock on each of the new Third and Fourth investment dates.
- No other changes to merger terms; previous conditions and consideration unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224035285/0001493152-24-035285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315224035285/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-035285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer